OncoMatch/Clinical Trials/NCT05061550
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Is NCT05061550 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Durvalumab · Oleclumab · Monalizumab · Dato-DXd · AZD0171 · Carboplatin · Cisplatin · Pemetrexed/Cisplatin · Pemetrexed/Carboplatin · Carboplatin/Paclitaxel · Volrustomig · Rilvegostomig — The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR sensitizing mutation
Participants with sensitising EGFR mutations
Excluded: ALK translocation
Participants with ... ALK translocations
Excluded: PD-L1 (CD274) expression <1%
Participants with baseline PD-L1 expression status <1% (Arms 6 and 7 only)
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB
Performance status
WHO OR ECOG 0–1
Demographics
Prior therapy
Cannot have received: immune-mediated therapy (anti-CTLA-4, anti-TIGIT, anti-PD-1, anti-PD-L1, anti-PD-L2, agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, anti-LIF agents, TROP2 targeting ADC, ADC containing a chemotherapy agent that inhibits TOP1 activity)
Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Participants who received agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, and anti-LIF agents are also excluded. Participants who have received previous treatment with a TROP2 targeting ADC or with another ADC containing a chemotherapy agent that inhibits TOP1 activity are also excluded.
Cannot have received: preoperative radiotherapy
Participants who have preoperative radiotherapy treatment as part of their care plan
Cannot have received: concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment
Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Little Rock, Arkansas
- Research Site · Los Angeles, California
- Research Site · Oakland, California
- Research Site · New Haven, Connecticut
- Research Site · Stuart, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05061550 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune-mediated therapy, preoperative radiotherapy, concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment disqualifies patients from enrollment.
Are patients with EGFR alterations eligible?
No. EGFR sensitizing mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK translocation is an exclusion criterion.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB is required.
Is there an age limit?
Yes. Patients must be 95 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages